AI assistant
IMMUNIC, INC. — Director's Dealing 2025
Jun 20, 2025
10196_dirs_2025-06-20_148dab67-0a08-46e8-9a1a-795e70e498e3.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4/A — Form 4/A
Issuer: IMMUNIC, INC. (IMUX)
CIK: 0001280776
Period of Report: 2025-06-04
Reporting Person: Vitt Daniel (Director, CEO and Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-06-04 | Common Stock | P | 15000 | $0.77 | Acquired | 29000 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-06-05 | Stock Option | $0.7729 | A | 1558000 | Acquired | 2035-06-05 | Common Stock (1558000) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 362877 | Indirect |
Footnotes
F1: The purchase was made in Euros and the price was converted into U.S. dollars based on the foreign currency exchange rate as of June 4, 2025 (at Euro 1.00 = U.S. dollar 1.1384).
F2: 362,877 shares of the Issuer's common stock are owned by Listrax UG (haftungsbeschrankt). The RP is Managing Director of Listrax UG and exercises voting and dispositive power over such shares.
F3: 25% of the shares underlying the option vest on the first anniversary of the grant date, with the remainder vesting in equal increments on each successive one-month anniversary thereafter for the next 36 months.